---
title: Nephrology CROs in Asia-Pacific
path: /indications/nephrology/apac
companies_count: 9
---

# Nephrology CROs in Asia-Pacific

9 published CROs match Nephrology in Asia-Pacific.

Locations in this set include United States, China, Australia, India, Japan, and South Korea.

Capabilities that show up most often in this set: Phase II Clinical Trials, Phase III Clinical Trials, Regulatory Affairs, EU EMA Regulatory Strategy, and US FDA Regulatory Strategy.

## Matching companies

- [Aragen Life Sciences](/companies/aragen)
  - Global CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
- [Emerald Clinical](/companies/emeraldclinical)
  - Global clinical research organization with 25+ years of expertise, headquartered in Singapore with operations across Asia-Pacific, EMEA, and the Americas. Specializes in renal, oncology, cardiovascular, and early-phase research with deep scientific leadership and proven operational excellence.
- [Fortrea](/companies/fortrea)
  - Fortrea is a leading CRO advancing clinical trials through patient-focused clinical solutions that accelerate clinical development and drive trial success.
- [KCAS Bio](/companies/kcasbio)
  - Leading bioanalytical CRO with 45+ years of experience, supporting 315+ approved drugs through bioanalysis, biomarker, immunogenicity, flow cytometry, and clinical kitting services across US, EU, and Australia facilities.
- [PPD](/companies/ppd)
  - PPD is a leading global contract research organization (CRO) and the clinical research business of Thermo Fisher Scientific.
- [PSI](/companies/appian)
  - PSI runs full-service Phase 2 and 3 clinical trials with a stated focus on on-time enrollment and over 90% repeat and referral business. Key therapeutic areas include oncology, GI, hematology, cell and gene therapy, neurology, and infectious diseases.
- [Pharmaron](/companies/pharmaron)
  - Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- [Syngene International](/companies/syngeneintl)
  - Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- [WuXi AppTec](/companies/wuxiapptec)
  - Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.